375 related articles for article (PubMed ID: 20512556)
1. Immune infiltration in human cancer: prognostic significance and disease control.
Fridman WH; Galon J; Dieu-Nosjean MC; Cremer I; Fisson S; Damotte D; Pagès F; Tartour E; Sautès-Fridman C
Curr Top Microbiol Immunol; 2011; 344():1-24. PubMed ID: 20512556
[TBL] [Abstract][Full Text] [Related]
2. Immune infiltration in human tumors: a prognostic factor that should not be ignored.
Pagès F; Galon J; Dieu-Nosjean MC; Tartour E; Sautès-Fridman C; Fridman WH
Oncogene; 2010 Feb; 29(8):1093-102. PubMed ID: 19946335
[TBL] [Abstract][Full Text] [Related]
3. Tertiary lymphoid structures in cancer and beyond.
Dieu-Nosjean MC; Goc J; Giraldo NA; Sautès-Fridman C; Fridman WH
Trends Immunol; 2014 Nov; 35(11):571-80. PubMed ID: 25443495
[TBL] [Abstract][Full Text] [Related]
4. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.
Dieu-Nosjean MC; Giraldo NA; Kaplon H; Germain C; Fridman WH; Sautès-Fridman C
Immunol Rev; 2016 May; 271(1):260-75. PubMed ID: 27088920
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment is multifaceted.
Sautès-Fridman C; Cherfils-Vicini J; Damotte D; Fisson S; Fridman WH; Cremer I; Dieu-Nosjean MC
Cancer Metastasis Rev; 2011 Mar; 30(1):13-25. PubMed ID: 21271351
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers.
Di Caro G; Bergomas F; Grizzi F; Doni A; Bianchi P; Malesci A; Laghi L; Allavena P; Mantovani A; Marchesi F
Clin Cancer Res; 2014 Apr; 20(8):2147-58. PubMed ID: 24523438
[TBL] [Abstract][Full Text] [Related]
7. Coordination of intratumoral immune reaction and human colorectal cancer recurrence.
Camus M; Tosolini M; Mlecnik B; Pagès F; Kirilovsky A; Berger A; Costes A; Bindea G; Charoentong P; Bruneval P; Trajanoski Z; Fridman WH; Galon J
Cancer Res; 2009 Mar; 69(6):2685-93. PubMed ID: 19258510
[TBL] [Abstract][Full Text] [Related]
8. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
9. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.
Becht E; Giraldo NA; Germain C; de Reyniès A; Laurent-Puig P; Zucman-Rossi J; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
Adv Immunol; 2016; 130():95-190. PubMed ID: 26923001
[TBL] [Abstract][Full Text] [Related]
10. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.
Germain C; Gnjatic S; Tamzalit F; Knockaert S; Remark R; Goc J; Lepelley A; Becht E; Katsahian S; Bizouard G; Validire P; Damotte D; Alifano M; Magdeleinat P; Cremer I; Teillaud JL; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
Am J Respir Crit Care Med; 2014 Apr; 189(7):832-44. PubMed ID: 24484236
[TBL] [Abstract][Full Text] [Related]
11. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
Pagès F; Kirilovsky A; Mlecnik B; Asslaber M; Tosolini M; Bindea G; Lagorce C; Wind P; Marliot F; Bruneval P; Zatloukal K; Trajanoski Z; Berger A; Fridman WH; Galon J
J Clin Oncol; 2009 Dec; 27(35):5944-51. PubMed ID: 19858404
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of the local inflammatory response in colorectal cancer.
Richards CH; Roxburgh CS; Powell AG; Foulis AK; Horgan PG; McMillan DC
Eur J Cancer; 2014 Jan; 50(2):309-19. PubMed ID: 24103145
[TBL] [Abstract][Full Text] [Related]
13. The immune microenvironment: a major player in human cancers.
Fridman WH; Remark R; Goc J; Giraldo NA; Becht E; Hammond SA; Damotte D; Dieu-Nosjean MC; Sautès-Fridman C
Int Arch Allergy Immunol; 2014; 164(1):13-26. PubMed ID: 24852691
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
Badoual C; Hans S; Rodriguez J; Peyrard S; Klein C; Agueznay Nel H; Mosseri V; Laccourreye O; Bruneval P; Fridman WH; Brasnu DF; Tartour E
Clin Cancer Res; 2006 Jan; 12(2):465-72. PubMed ID: 16428488
[TBL] [Abstract][Full Text] [Related]
15. Development of Tools for the Selective Visualization and Quantification of TLS-Immune Cells on Tissue Sections.
Klein C; Devi-Marulkar P; Dieu-Nosjean MC; Germain C
Methods Mol Biol; 2018; 1845():47-69. PubMed ID: 30141007
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.
Remark R; Alifano M; Cremer I; Lupo A; Dieu-Nosjean MC; Riquet M; Crozet L; Ouakrim H; Goc J; Cazes A; Fléjou JF; Gibault L; Verkarre V; Régnard JF; Pagès ON; Oudard S; Mlecnik B; Sautès-Fridman C; Fridman WH; Damotte D
Clin Cancer Res; 2013 Aug; 19(15):4079-91. PubMed ID: 23785047
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cells and Toll-like receptors in tumor immunity.
Wang RF; Peng G; Wang HY
Semin Immunol; 2006 Apr; 18(2):136-42. PubMed ID: 16469504
[TBL] [Abstract][Full Text] [Related]
19. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
Badoual C; Hans S; Merillon N; Van Ryswick C; Ravel P; Benhamouda N; Levionnois E; Nizard M; Si-Mohamed A; Besnier N; Gey A; Rotem-Yehudar R; Pere H; Tran T; Guerin CL; Chauvat A; Dransart E; Alanio C; Albert S; Barry B; Sandoval F; Quintin-Colonna F; Bruneval P; Fridman WH; Lemoine FM; Oudard S; Johannes L; Olive D; Brasnu D; Tartour E
Cancer Res; 2013 Jan; 73(1):128-38. PubMed ID: 23135914
[TBL] [Abstract][Full Text] [Related]
20. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
